Retatrutide represents the next generation of weight management treatments currently generating significant medical interest across the British healthcare landscape. As a triple hormone receptor agonist targeting GIP GLP 1 and glucagon receptors clinical trials demonstrate unprecedented efficacy for substantial weight reduction and metabolic improvement. Researchers and clinicians in the United Kingdom are closely monitoring its […]